Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

Simple item page
dc.contributor.authorOchoa-Grullón, J. et al.
dc.contributor.authorS. Sánchez-Ramón
dc.contributor.authorBenavente Cuesta, Celina
dc.contributor.authorPérez López, César
dc.contributor.authorPeña Cortijo, Ascensión
dc.contributor.authorMateos-Aparicio Morales, Gregoria
dc.contributor.authorWilliams, J.L.
dc.contributor.authorFernández Arquero, Miguel
dc.contributor.authorRecio Hoyas, María José
dc.date.accessioned2024-01-11T17:02:55Z
dc.date.available2024-01-11T17:02:55Z
dc.date.issued2020-01
dc.description.abstractAn increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab responses to pneumococcal and Salmonella typhi pure polysaccharide immunization in a cohort of 42 HM patients and 24 healthy-controls. Pre-post specific Ab concentrations were measured by ELISA at 4 weeks. Globally, significantly lower Typhim Vi (TV) seroprevalence (9%) compared to 23-valent pneumococcal polysaccharide vaccine (PPV) (76%) (p <0.001) was observed. TV non responders (88%) were higher than PPV non responders (62%) (p <0.0001) and correlated better to infectious history. By ROC analysis, pre-post 5-fold TV increase was the best cut-off to discriminate HM with recurrent infections and controls (sensitivity 91%, specificity 100%). Despite the small sample cohort, our results suggest that specific anti-S typhi Ab response is a useful complementary assay in the diagnosis and management decision of SID to HM.
dc.description.departmentDepto. de Inmunología, Oftalmología y ORL
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationOchoa-Grullón J, Benavente Cuesta C, Pérez López C, Peña Cortijo A, Rodríguez de la Peña A, Álvarez Carmona A, Mateo Morales M, Llano-Hernández K, Williams LJ, Rodríguez de Frías E, Guevara-Hoyer K, Cordero Torres G, Orte C, Fernández-Arquero M, Fernández-Paredes L, Serrano-García I, Recio MJ, Pérez de Diego R, Martínez R, Sánchez-Ramón S. Clin Immunol. 2020 Jan;210:108307.
dc.identifier.doi10.1016/j.clim.2019.108307
dc.identifier.issn1521-6616
dc.identifier.officialurlhttps://www.sciencedirect.com/journal/clinical-immunology
dc.identifier.urihttps://hdl.handle.net/20.500.14352/92618
dc.journal.titleClinical Immunology
dc.language.isoeng
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCE
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.cdu612.017
dc.subject.keywordHaematological malignancies
dc.subject.keywordHypogammaglobulinemia
dc.subject.keywordPneumo23
dc.subject.keywordSpecific polysaccharide ab response
dc.subject.keywordTyphim vi
dc.subject.ucmInmunología
dc.subject.unesco2412 Inmunología
dc.titleEvaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number210
dspace.entity.typePublication
relation.isAuthorOfPublication738fc59c-84c5-487c-bb7d-e392571e5479
relation.isAuthorOfPublication98fa60db-87c9-4455-84a5-812a8e3dc695
relation.isAuthorOfPublication61097257-cbc3-4a0b-936a-9d07bc0cb6ce
relation.isAuthorOfPublication7ba10288-3db7-4ce4-81a7-51fbbed78bb2
relation.isAuthorOfPublicationfbe74799-7e79-4575-8569-13513d454d3e
relation.isAuthorOfPublication9ee6ea4a-b0a0-468e-9b6f-21156771b804
relation.isAuthorOfPublication436ddd6b-73c0-4f41-9d60-f15490326809
relation.isAuthorOfPublication.latestForDiscovery738fc59c-84c5-487c-bb7d-e392571e5479
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ClinImmunol_20.pdf
Size:
692.12 KB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos